Psychometric Properties of the Osteoporosis-Specific Morisky Medication Adherence Scale in Postmenopausal Women with Osteoporosis Newly Treated with Bisphosphonates

Abstract

Spanish

French

Background:

Poor adherence to oral osteoporosis medications is common. Strategies for improving adherence begin with identification of the problem. The 8-item Morisky Medication Adherence Scale for self-reported adherence to antihypertensive medications was modified for assessing adherence to oral osteoporosis medications. An evaluation of the measurement properties of the Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) was needed.

Objective:

To examine the psychometric properties of the OS-MMAS in women with postmenopausal osteoporosis.

Methods:

Five hundred women aged 55 years and older with osteoporosis who were newly prescribed daily or weekly oral bisphosphonates between May 15, 2010, and August 15, 2010, were randomly selected from Kaiser Permanente Southern California, a large integrated health care delivery system, and mailed a self-administered survey that included the 8-item OS-MMAS, Self-Efficacy for Appropriate Medication Use Scale (SEAMS), Beliefs about Medicines Questionnaire (BMQ), Treatment Satisfaction Questionnaire for Medication (TSQM), Gastrointestinal Symptom Rating Scale (GSRS), and 12-item Short-Form Health Survey (SF-12v2). OS-MMAS scores can range from 0 to 8, with higher scores indicating better medication adherence. Internal consistency reliability was evaluated using Cronbach α coefficient. Test-retest reliability was assessed using intraclass correlation coefficients (ICCs) in a subset of 102 participants. Construct validity was assessed using confirmatory (actor analysis and correlations between OS-MMAS and related measures.

Results:

Of 197 participants, 150 reported that they were still taking their bisphosphonate at the time of the survey and completed the OS-MMAS. Overall, 30.7%, 32.7%, and 36.7% had tow, medium, and high OS-MMAS scores (<6, 6 to <8, and 8, respectively). Cronbach α was 0.82 and the ICC was 0.77. Convergent validity was supported by significant correlations with SEAMS, BMQ necessity, and TSQM scores. In confirmatory factor analysis, a single-factor scale was supported.

Conclusions:

The OS-MMAS showed strong psychometric properties with good reliability and construct validity and may provide a valuable assessment of self-reported medication adherence in women newly prescribed oral osteoporosis medications.

Keywords

adherence bisphosphonates Morisky scale postmenopausal osteoporosis reliability validity

Get full access to this article

View all access options for this article.

References

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785–95.

National Osteoporosis Foundation. Fast facts, www.nof.org/node/40 (accessed 15 Jul 2011).

Dempster

, Lindsay

. Pathogenesis of osteoporosis. Lancet 1993; 341:797–801.

Burge

, Dawson-Hughes

, Solomon

, Wong

, King

, Tosteson

. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007; 22:465–75. DOI 10.1359/jbmr.061113

Boonen

, Laan

, Barton

, Watts

. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of in tention-to-treat studies. Osteoporos Int 2005; 16:1291–8. DOI 10.1007/s00198-005-1945-x

Cranney

, Guyatt

, Griffith

, Wells

, Tugwell

, Rosen

. Metaanalyses of therapies for postmenopausal osteoporosis. K: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23:570–8.

Cummings

, Black

, Thompson

. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280:2077–82.

Siris

, Harris

, Rosen

. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81:1013–22.

Weycker

, Macarios

, Edelsberg

, Oster

. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 2007; 18:271–7. DOI 10.1007/s00198-006-0230-y

10.

Kothawala

, Badamgarav

, Ryu

, Miller

, Haibert

. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007; 82:1493–501.

11.

Huybrechts

, Ishak

, Caro

. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006; 38:922–8. DOI 10.1016/j.bone.2005.10.022

12.

Tosteson

, Grove

, Hammond

. Early discontinuation of treatment for osteoporosis. Am J Med 2003; 115:209–16.

13.

Recker

, Gallagher

, MacCosbe

. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80:856–61.

14.

Lekkerkerker

, Kanis

, Alsayed

. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007; 18:1311–7. DOI 10.1007/S00198-007-0410-4

15.

Warriner

, Curtis

. Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol 2009; 21:356–62. DOI 10.1097/BOR.0b013e32832c6aa4

16.

Krousel-Wood

, Islam

, Webber

, Re

, Morisky

, Muntner

. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care 2009; 15:59–66.

17.

Morisky

, Ang

, Krousel-Wood

, Ward

. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008; 10:348–54.

18.

Atkinson

, Sinha

, Hass

. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2:12. DOI 10.1186/1477-7525-2–12. Those seeking information regarding or permission to use the TSQM are directed to Quintiles, Inc. at www.quintiles.com/TSQM or TSQM@quintiles.com.

19.

Dimenas

, Glise

, Hallerback

, Hernqvist

, Svedlund

, Wiklund

. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28:681–7.

20.

Home

, Weinman

, Hankins

. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychology and Health 1999; 14:1–24.

21.

Revicki

, Wood

, Wiklund

, Crawley

. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7:75–83.

22.

Risser

, Jacobson

, Kripalani

. Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. J Nurs Meas 2007; 15:203–19.

23.

Ware

Jr , Kosinski

, Keller

. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34:220–33.

24.

Gorsuch

. Factor analysis. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1983.

25.

Tinsley

HEA

, Tnisley

. Uses of factor analysis in counseling psychology research. J Counseling Psychology 1987; 34:414–24.

26.

Cronbach

. Coefficient alpha and internal structure tests. Psychometrika 1951; 16:297–334.

27.

Leidy

, Revicki

, Geneste

. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999; 2:113–27. DOI 10.1046/j.1524-4733.1999.02210.x

28.

Lin

. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989; 45:255–68.

29.

Landis

, Koch

. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159–74.

30.

Bentler

. Comparative fit indexes in structural models. Psychol Bull 1990; 107:238–46.

31.

Browne

, Cudeck

. Alternative ways of assessing model fit. Socio Methods Res 1992; 21:230–59.

32.

Hatcher

. A step-by-step approach to using the SAS system for factor analysis and structural equation modeling. Cary, NC: SAS Publishing, 1994.

33.

Osterberg

, Blaschke

. Adherence to medication. N Engl J Med 2005; 353:487–97. DOI 10.1056/NEJMra050100

34.

Palacios

, Sanchez-Borrego

, Neyro

, Quereda

, Vazquez

, Perez

. Knowledge and compliance from patients with postmenopausal osteoporosis treatment. Menopause Int 2009; 15:113–9. DOI 10.1258/mi.2009.009029

35.

Turbi

, Herrero-Beaumont

, Acebes

. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004; 26:245–56.

36.

Breuil

, Cortet

, Cotte

. Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic postmenopausal women. Osteoporos Int 2012; 23:445–55. DOI 10.1007/S00198-011-1555-8

37.

Morisky

, Green

, Levine

. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24:67–74.

38.

DeVellis

. Reliability (24-42). In: Scale development–theory and applications applied social research methods series. Volume 26. Newbury Park, CA: Sage Publications Inc., 1991.

39.

Clifford

, Barber

, Home

. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the Necessity-Concerns Framework. J Psychosom Res 2008; 64:41–6. DOI 10.1016/j.jpsychores.2007.05.004

40.

McHorney

, Gadkari

. Individual patients hold different beliefs to prescription medications to which they persist vs nonpersist and persist vs nonfulfill. Patient Prefer Adherence 2010; 4:187–95.